title: Long-term administration of inulin-type fructans has no significant lipid-lowering effect in normolipidemic humans.
abstract: Short-term studies have shown that the addition to diet of inulin-type fructans, a nondigestible carbohydrate, may have a plasma lipid-lowering effect in humans. Whether this beneficial effect persists during long-term administration has not been determined. The study was aimed at determining whether a prolonged (6 months) administration of inulin-type fructans to healthy subjects has a lipid-lowering action. In a double-blind, randomized, placebo-controlled study, 17 healthy subjects were studied before and after 6 months of daily administration of placebo (8 subjects) or 10 g of a mix of inulin and oligofructose (9 subjects). During this 6-month period, they consumed their usual diet and did not modify their everyday way of life. We measured plasma lipid concentrations; cholesterol synthesis and hepatic lipogenesis; and adipose tissue and circulating mononuclear cell messenger RNA concentrations of key regulatory genes of cholesterol metabolism. Compared with the administration of placebo, the administration of inulin-type fructans had no effect on plasma triacylglycerol concentrations and hepatic lipogenesis and induced only a nonsignificant trend for decreased plasma total and low-density lipoprotein cholesterol levels and increased high-density lipoprotein cholesterol concentration. Cholesterol synthesis was not significantly modified. Of all the messenger RNA concentrations measured, none was significantly modified by the administration of inulin-type fructans. In conclusion, contrary to what was observed in short-term studies, we observed no significant beneficial effect of a long-term (6-month) administration of inulin-type fructans on plasma lipids in healthy human subjects.
authors.affiliation: INSERM U 499, Faculté RTH Laënnec, IFR 62, Université Claude Bernard Lyon, 69008 Lyon, France.
authors.forename: Fabien
authors.initials: F
authors.lastname: Forcheron
authors.forename: Michel
authors.initials: M
authors.lastname: Beylot
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000328:Adult; D001823:Body Composition / Q000502:physiology; D002784:Cholesterol / Q000378:metabolism; D004032:Diet; D004734:Energy Metabolism / Q000502:physiology; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005630:Fructans / Q000494:pharmacology*; D006728:Hormones / Q000097:blood; D006801:Humans; D000960:Hypolipidemic Agents; D007444:Inulin / Q000494:pharmacology*; D007700:Kinetics; D008055:Lipids / Q000096:biosynthesis / Q000097:blood*; D008297:Male; D009000:Monocytes / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D014280:Triglycerides / Q000097:blood
chemical_list: D005230:Fatty Acids, Nonesterified; D005630:Fructans; D006728:Hormones; D000960:Hypolipidemic Agents; D008055:Lipids; D012333:RNA, Messenger; D014280:Triglycerides; D007444:Inulin; D002784:Cholesterol